The rounds this investor is named on, who it invests beside, and where it shows up.
Named on 6 rounds in the feed, most often at Series D+ and in Biotech.
At XGEN we specialize in early stage investments in private research & development companies in the life sciences sector.
Venture capitalMilan, Italyxgenventure.comRounds from 2023-11-14 to 2026-10-19
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Nouscom Nouscom is a biotech company selling cancer-preventing vaccine candidates primarily to healthcare providers and clinical trial organizations. | Series D Verified against 4 of 10 sources | $133.8M | 2026-10-19 | [ PART ] |
Nouscom A clinical-stage, cancer interception focused biotech developing next-generation immunotherapies | Series D |
| $134.7M |
| 2026-10-19 |
| [ PART ] |
Aptadir Therapeutics A preclinical biotech company developing a new class of RNA therapeutics | Seed Verified against 1 of 40 sources | $44.7M | 2026-09-29 | [ PART ] |
Dialybrid A clinical-stage medical device company developing novel arteriovenous vascular grafts for hemodialysis | Series A Verified against 9 sources | $17.1M | 2026-09-22 | [ LEAD ] |
AAVantgarde AAVantgarde is a clinical-stage biotechnology company developing next-generation therapies for inherited retinal diseases with high unmet need | Series B Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $141M | 2025-11-03 | [ PART ] |
Nouscom A clinical-stage, cancer interception focused biotech developing next-generation immunotherapies | Series C Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $72.4M | 2023-11-14 | [ PART ] |